Hsbc Holdings PLC boosted its position in shares of Syneos Health, Inc. (NASDAQ:SYNH – Get Rating) by 2.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,807 shares of the company’s stock after acquiring an additional 562 shares during the period. Hsbc Holdings PLC’s holdings in Syneos Health were worth $1,379,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in SYNH. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in shares of Syneos Health during the 2nd quarter valued at about $28,000. CWM LLC grew its stake in shares of Syneos Health by 51.7% in the 3rd quarter. CWM LLC now owns 634 shares of the company’s stock valued at $30,000 after purchasing an additional 216 shares during the period. Wipfli Financial Advisors LLC acquired a new position in shares of Syneos Health in the 3rd quarter worth approximately $31,000. Meeder Asset Management Inc. lifted its position in shares of Syneos Health by 181.8% during the 2nd quarter. Meeder Asset Management Inc. now owns 465 shares of the company’s stock worth $33,000 after buying an additional 300 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its stake in Syneos Health by 147.1% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 897 shares of the company’s stock valued at $42,000 after buying an additional 534 shares in the last quarter. Institutional investors and hedge funds own 93.51% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on SYNH. JPMorgan Chase & Co. lowered shares of Syneos Health from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $30.00 to $28.00 in a report on Monday, February 13th. Barclays raised their price target on Syneos Health from $30.00 to $45.00 and gave the company an “underweight” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft reduced their price objective on Syneos Health from $77.00 to $51.00 in a research note on Wednesday, November 9th. Citigroup lowered their target price on Syneos Health from $55.00 to $30.00 and set a “neutral” rating for the company in a research note on Sunday, November 6th. Finally, Robert W. Baird upped their price target on shares of Syneos Health from $42.00 to $51.00 and gave the stock an “outperform” rating in a research report on Friday, February 17th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Syneos Health currently has an average rating of “Hold” and an average target price of $54.00.
Syneos Health Stock Performance
Syneos Health (NASDAQ:SYNH – Get Rating) last announced its quarterly earnings data on Thursday, February 16th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.08. Syneos Health had a net margin of 4.94% and a return on equity of 13.19%. The business had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.29 billion. Equities analysts anticipate that Syneos Health, Inc. will post 2.85 earnings per share for the current year.
About Syneos Health
Syneos Health, Inc engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process.
See Also
- Get a free copy of the StockNews.com research report on Syneos Health (SYNH)
- Jack in the Box Pops On Tasty Results, Robust Outlook
- How Low Can Lowe’s Companies Go?
- Ambarella: An AI Play In The Making
- Wendy’s Price Firms After Sizzling Quarter And Juicy Outlook
- Terran Orbital’s New $2.4 Billion Contract is a Game Changer
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.
